Innovating Works

CATCH

Financiado
Novel T cell therapies against lymphocytic leukaemia
Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia globally and can rarely be cured. Despite recent advances, the efficacy of promising autologous T cell-based therapies, such as CAR-T technology and bi-/tri-... Chronic lymphocytic leukaemia (CLL) is the most common type of leukaemia globally and can rarely be cured. Despite recent advances, the efficacy of promising autologous T cell-based therapies, such as CAR-T technology and bi-/tri-specific antibodies, has been disappointing. This stems from a T cell dysfunction in this disease setting: altered T cell skewing, impaired metabolic plasticity, and disrupted T-cell functioning. Prof. Arnon Kater's group studies alternative activation pathways to overcome T cell dysfunction and stimulate an immune response. CATCH will explore the technical and commercial feasibility of alternative T-cell activation, through CAR-T and tri-specific antibody technologies. To reach proof-of-concept stage, in this project we will: 1) Validate the efficacy of two applications (CAR-T, tri-specific antibody) by achieving T-cell activation and killing target cells in in-vitro CLL samples and live specimens. 2) Perform a thorough IP landscape analysis, establish Freedom-to-Operate, and define an IP strategy. 3) Engage with key stakeholders to gather feedback and advise from key perspectives (patient, clinical, industry), conduct market research to discover potential customers/industrial partners, analyse competitors and identify a feasible roadmap to commercialisation. 4) Formulate a detailed business case to guide the commercialisation of CATCH. ver más
31/12/2023
Academisch Medisch...
150K€
Perfil tecnológico estimado
Duración del proyecto: 18 meses Fecha Inicio: 2022-06-30
Fecha Fin: 2023-12-31

Línea de financiación: concedida

El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-12-31
Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:
ERC-2022-POC2: ERC PROOF OF CONCEPT GRANTS2
Cerrada hace 2 años
Presupuesto El presupuesto total del proyecto asciende a 150K€
Líder del proyecto
Academisch Medisch Centrum AMC No se ha especificado una descripción o un objeto social para esta compañía.
Perfil tecnológico TRL 4-5